These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 2534057

  • 21. The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment.
    Glass B, Uharek L, Gaska T, Gassmann W, Löffler H, Müller-Ruchholtz W.
    Bone Marrow Transplant; 1993; 12 Suppl 3():S41-7. PubMed ID: 8124257
    [Abstract] [Full Text] [Related]

  • 22. Effects of T cell depletion in radiation bone marrow chimeras. II. Requirement for allogeneic T cells in the reconstituting bone marrow inoculum for subsequent resistance to breaking of tolerance.
    Sykes M, Sheard MA, Sachs DH.
    J Exp Med; 1988 Aug 01; 168(2):661-73. PubMed ID: 3045249
    [Abstract] [Full Text] [Related]

  • 23. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z, Shatry A, Deyev V, Podack E, Mammolenti M, Blazar BR, Yagita H, Levy RB.
    Biol Blood Marrow Transplant; 2005 Aug 01; 11(8):576-86. PubMed ID: 16041307
    [Abstract] [Full Text] [Related]

  • 24. Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation.
    Hossain MS, Roback JD, Lezhava L, Hillyer CD, Waller EK.
    Biol Blood Marrow Transplant; 2005 Mar 01; 11(3):169-80. PubMed ID: 15744235
    [Abstract] [Full Text] [Related]

  • 25. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.
    Chen C, Cao J, Zeng L, Li Y, Wang D, Xu K.
    Transplant Proc; 2011 Jun 01; 43(5):2041-8. PubMed ID: 21693322
    [Abstract] [Full Text] [Related]

  • 26. Abrogation of bone marrow allograft resistance in mice by increased total body irradiation correlates with eradication of host clonable T cells and alloreactive cytotoxic precursors.
    Schwartz E, Lapidot T, Gozes D, Singer TS, Reisner Y.
    J Immunol; 1987 Jan 15; 138(2):460-5. PubMed ID: 3098843
    [Abstract] [Full Text] [Related]

  • 27. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
    Jones MS, Riley R, Hamilton BL, Paupe J, Perez D, Levy RB.
    Bone Marrow Transplant; 1994 Nov 15; 14(5):725-35. PubMed ID: 7889005
    [Abstract] [Full Text] [Related]

  • 28. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S.
    Clin Transpl; 1996 Nov 15; ():281-90. PubMed ID: 9286578
    [Abstract] [Full Text] [Related]

  • 29. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK, deMagalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD.
    Bone Marrow Transplant; 2003 Jan 15; 31(2):121-8. PubMed ID: 12621494
    [Abstract] [Full Text] [Related]

  • 30. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD, Drobyski WR, Truitt RL.
    Bone Marrow Transplant; 1993 Apr 15; 11(4):329-36. PubMed ID: 8485480
    [Abstract] [Full Text] [Related]

  • 31. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA, Vesole DH, Horowitz M, Zhang MJ, Juckett M, Drobyski WR.
    Biol Blood Marrow Transplant; 2001 Apr 15; 7(11):620-30. PubMed ID: 11760150
    [Abstract] [Full Text] [Related]

  • 32. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, Murphy WJ.
    J Clin Invest; 1998 May 01; 101(9):1835-42. PubMed ID: 9576746
    [Abstract] [Full Text] [Related]

  • 33. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L, Glass B, Zeis M, Dreger P, Steinmann J, Löffler H, Schmitz N.
    Exp Hematol; 1998 Feb 01; 26(2):93-9. PubMed ID: 9472798
    [Abstract] [Full Text] [Related]

  • 34. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
    Blazar BR, Taylor PA, Snover DC, Bluestone JA, Vallera DA.
    J Immunol; 1993 Jan 01; 150(1):265-77. PubMed ID: 8417127
    [Abstract] [Full Text] [Related]

  • 35. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G, Truitt RL, Johnson BD.
    Biol Blood Marrow Transplant; 2006 Apr 01; 12(4):397-407. PubMed ID: 16545723
    [Abstract] [Full Text] [Related]

  • 36. Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease.
    Ewing P, Miklos S, Olkiewicz KM, Müller G, Andreesen R, Holler E, Cooke KR, Hildebrandt GC.
    Exp Hematol; 2007 Jan 01; 35(1):155-63. PubMed ID: 17198884
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The effect of T lymphocyte depletion on susceptibility to influenza virus infection and development of anti-viral immunity in lethally irradiated mice reconstituted with syngeneic bone marrow grafts.
    Mumcuoglu M, Zakay-Rones Z, Parag G, Weiss L, Slavin S.
    Bone Marrow Transplant; 1987 Dec 01; 2(4):403-12. PubMed ID: 3332187
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR, Taylor PA, Vallera DA.
    J Immunol; 1994 Apr 01; 152(7):3665-74. PubMed ID: 8144942
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.